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Abstract
Background Many patients with cancer experience aggressive
care towards the end of life (EOL) despite evidence of an
association with poor outcomes such as prolonged pain and
overall dissatisfaction with care.
Purpose To investigate socio-demographic, clinical and com-
munity health care service factors associated with aggressive
EOL cancer care.
Methods An analysis of pooled data from two mortality
follow-back surveys was performed. Aggressive EOL care
was defined as greater than or equal to one of the following
indicators occurring during the last 3 months of life: greater
than or equal to two emergency department visits, ≥30 days in
hospital and death in hospital.
Results Of the 681 included patients, 50.1 % were men and
mean age at death was 75 years. The majority of patients
(59.3 %, 95 % confidence interval (CI) 55.6–63.0 %) experi-
enced at least one indicator of aggressive EOL care: 29.7 %
experienced greater than or equal to two ED visits, 17.1% spent
≥30 days in hospital and 37.9 % died in hospital. Patients with
prostate or haematological cancer were more likely to experi-
ence aggressive EOL care (adjusted odds ratio (AOR) 4.36,
95 % CI 1.39–13.70, and 4.16, 95 % CI 1.38–12.47, respec-
tively, reference group lung cancer). Patients who received
greater than five general practitioner (GP) home visits (AOR
0.37, 95 % CI 0.17–0.82, reference group no GP visits) or had
contact with district nursing (AOR 0.48, 95 % CI 0.28–0.83,
reference group no contact) or contact with community pallia-
tive care services (AOR 0.27, 95 % CI 0.15–0.49, reference
group no contact) were less likely to experience aggressive
EOL care. No association was found between aggressive EOL
care and patients’ age, gender, marital, financial or health status.
Conclusions Community health care services, in particular
contact with community palliative care, are associated with a
significant reduction in the odds of cancer patients receiving
aggressive EOL care. Expansion of such services may help
address the current capacity crises faced by many acute health
care systems.
Keywords Neoplasms . Palliative care . Terminal care .
Community health services . Emergency service . Hospital .
Hospital mortality
Introduction
Towards the end of life (EOL), patients with cancer wish to be
comfortable, be afforded dignity and privacy, and have the
opportunity to achieve a sense of completion [1–4]. They also
wish to avoid overly ‘intensive’ or ‘aggressive’ medical care
which can be defined as care that focuses mostly or exclusive-
ly on disease-modifying treatments at the expense of good
symptom management and/or advance care planning. In
2003, Earle and colleagues identified several markers of po-
tentially overly aggressive EOL cancer care including multi-
ple emergency department (ED) visits towards the EOL, a
high number of days spent in hospital or intensive care to-
wards the EOL, death in hospital and an underuse of hospice
services [5]. Since then, several studies have further supported
these findings with evidence of an association between ag-
gressive EOL care and poor symptom control, reduced patient
quality of life and an increased risk of psychiatric illness in
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bereaved caregivers [6–8]. Furthermore, in a randomised con-
trolled trial of early palliative care for patients with advanced
non-small cell lung cancer, Temel and colleagues found that
overly aggressive EOL care may even shorten survival [9].
From a societal perspective, it is important to consider the
cost-effectiveness of any health care service delivered. In the
USA >10 % of the total health care budget and as much as
30 % of the Medicare budget are spent on care for those in the
last year of life [10, 11]. In the UK expenditure is similar with
an estimated 20% of the National Health Service budget spent
on care for those in the last year of life [12]. For cancer pa-
tients, health care spending has been shown to increase sub-
stantially in the months prior to death, with the additional costs
being mostly attributable to an increased use of acute health
care services such as unplanned hospital admissions and ED
visits [11, 13, 14].
Yet, despite these potentially negative outcomes for both
individuals and society, EOL cancer care is becoming increas-
ingly aggressive over time [15–19]. In a population-based
retrospective study of Medicare data, Earle and colleagues
reported significant increases over time in the proportion of
cancer patients with more than one ED visit (7.2 vs. 9.2 %;
P<0.001), an acute hospitalisation (7.8 vs. 9.1 %; P=0.008)
or admission to intensive care (7.1 vs. 9.4 %; P=0.009) in the
last month of life [15]. A number of studies have investigated
this trend with several associated factors identifying gender,
ethnicity and age as important determinants [20–24]. Howev-
er, evidence of an association with clinical characteristics and
community health care services is limited [25, 26]. The aim of
our study was therefore to investigate socio-demographic,
clinical and community health care service factors associated
with aggressive EOL care for a cohort of 681 cancer
decedents.
Methods
Study design and setting
We analysed pooled data from two mortality follow-back
studies: the QUALYCARE study [27] and the International
Access, Rights and Empowerment (IARE) study [28]. Mor-
tality follow-back studies involve surveying a cohort of dece-
dents’ significant others to gain information regarding the
EOL [29]. Through their design they address a number of
challenges commonly encountered when researching EOL
care including the accurate identification of people at the
EOL and the often high rates of participant withdrawal (typi-
cally due to ill health) that are seen with prospectively de-
signed studies [29, 30]. In both the QUALYCARE and IARE
studies, bereaved relatives/significant others were surveyed
(via a postal questionnaire) regarding the care received by
their family member/friend in the last 3 months of life. Both
studies were conducted across London, collectively
representing a socially and economically diverse urban popu-
lation. All participants had access to free health care at the
point of delivery through the UK’s National Health Service;
however, within this broader context, there were important
differences between the study samples with regard to the
EOL care packages provided; the IARE study sampled pa-
tients, all of whom had accessed specialist palliative care ser-
vices prior to death, whereas the QUALYCARE study includ-
ed patients who had accessed generalist, specialist or no pal-
liative care services prior to death. Our pooled study sample
therefore provided us with information regarding the EOL
care experiences of cancer patients across a range of health
care packages and levels of palliative care input. Further in-
formation regarding each of the original studies is available
elsewhere [27, 28].
Study population
Eligibility criteria for each of the original studies are described
in Table 3 Appendix. For our analysis, inclusion criteria were
as follows: (1) bereaved caregiver aged ≥18 years at time of
survey completion, (2) family member/friend died from can-
cer (ICD-10 codes C00 to C97) and were ≥18 years at time of
death, and (3) registration of death occurred 4 to 10 months
prior to survey completion.
Bereaved caregivers of patients’whose underlying cause of
death was due to non-malignant disease were excluded.
Study questionnaire
The questionnaire was developed using cognitive
interviewing for the QUALYCARE study [31] and then
adapted for use by the IARE study. Both questionnaire ver-
sions include five questions about the deceased’s health state
3 months prior to death (using the EuroQol Five-Dimensional
Questionnaire (EQ5D-3L) [32]) and several questions regard-
ing the number and type of health care services used during
the deceased’s last 3 months of life.
Outcome measure and explanatory variables
For our primary outcome, we calculated a composite mea-
sure, based on markers of potentially aggressive EOL can-
cer care developed by Earle and colleagues [5, 33], where
we scored each patient one point per occurrence of any of
the following three indicators: greater than or equal to two
ED visits in the last 3 months of life, ≥30 days in hospital
in the last 3 months of life and death in hospital. We then
dichotomised the composite score into two groups: those
who experienced no indicators of aggressive EOL care
(composite score=0) and those who experienced at least
one indicator (composite score=1–3).
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We examined three groups of variables potentially associ-
ated with our primary outcome: socio-demographics, clinical
characteristics and community health care service factors.
Socio-demographics included age at death (categorised in-
to five groups; <60 (reference), 60–69, 70–79, 80–89 and 90+
years), gender (reference female), marital status (married or
with partner (reference), widowed, divorced/ separated and
single) and living circumstances dichotomised as living with
others (reference) or living alone. A subjective measure of
patients’ financial hardship was reported from five possible
categories and dichotomised for analysis into those described
as living comfortably (reference) compared to all other groups
(doing alright, just about getting by, finding it quite difficult
and finding it very difficult).
Clinical characteristics included patients’ health state
3 months prior to death and underlying cancer diagnosis.
Health state was measured using the EQ5D-3L [32] which
includes questions on mobility, ability to self-care, activity
level, pain/discomfort and anxiety/depression. Underlying
type of cancer was categorised into seven groups (lung (refer-
ence), breast, prostate, gastrointestinal tract, haematological,
unknown primary and other).
Use of community health care services in the last 3 months
of life included the number of general practitioner (GP) home
visits (categorised as none (reference), one to five and greater
than five visits), contact with community palliative care ser-
vices (yes or no (reference)), and contact with district nursing
(yes or no (reference)). Community palliative care services
were defined as those that specifically provided palliative
and/or EOL care to patients in non-hospital settings and in-
cluded services such as Hospice at Home and Marie Curie or
Macmillan nursing. District nursing was defined as any other
nursing care (i.e. not exclusively palliative or EOL care nurs-
ing) received by patients in non-hospital settings such as the
patients’ home.
Statistical analysis
We used summary statistics to report patient demographic data
and describe the aggressiveness of EOL care experienced.
Differences between patients who did and did not experience
aggressive care were tested using a chi-squared test.
The likelihood of patients experiencing aggressive EOL
care was investigated using multivariable logistic regression,
where we calculated adjusted odds ratios (AORs) and their
corresponding 95% confidence intervals (CIs). Based on find-
ings of a recently published systematic review [24], the logis-
tic model was constructed with the following variables includ-
ed a priori: age, gender, financial status, marital status, type of
cancer and contact with palliative care services. All additional
variables were included if found to be significant (p<0.10) at
univariate analysis. We conducted sensitivity analysis to
explore the potential impact to our findings from the two dif-
ferent study samples.
Stata/IC 13 (STATA, College Station, TX, USA) was used
for all statistical analysis.
Results
The pooled dataset contains survey responses from 681 be-
reaved caregivers from across five London health regions
(QUALYCARE n=554, IARE n=127).
Mean age at death was 75 years; 50.1 % were men. Most
lived with others prior to death (69.7 %). The two most com-
mon diagnoses were gastrointestinal cancer (24.5 %) and lung
cancer (21.3 %) (Table 1).
Most patients in our sample (59.3 % (95 % CI 55.6–
63.0 %)) experienced at least one indicator of aggressive care
during the last 3 months of life: 29.7 % experienced greater
than or equal to two ED visits, 17.1 % spent ≥30 days in
hospital and 37.9 % died in hospital (Fig. 1). The median
composite score of aggressive EOL care was 1 (range 0 to 3).
Relative to those with lung cancer, patients with prostate or
haematological cancer were significantly more likely to expe-
rience aggressive care during their last 3 months of life (AOR
4.36, 95 % CI 1.39–13.70, and AOR 4.16, 95 % CI 1.38–
12.47, respectively). No association was found between ag-
gressive EOL care and cancer patients’ health status 3 months
prior to death (Table 2).
Patients who had contact with community health care ser-
vices (GP home visits, district nursing, and community palli-
ative care) were significantly less likely to experience aggres-
sive care during their last 3 months of life (Table 2). For GP
home visits, an incremental pattern was found whereby pa-
tients with greater than five visits had a greater reduction in
odds than those who had one to five visits (AOR 0.37, 95 %
CI 0.17–0.82, and AOR 0.59, 95%CI 0.35–1.00, respectively
(reference group no GP home visit)). Compared to patients
who had no contact with district nursing, those with contact
were less likely to experience aggressive EOL care (AOR
0.48, 95 % CI 0.28–0.83); however, the greatest reduction in
odds was found for cancer patients who had contact with
community palliative care services (AOR 0.27, 95 % CI
0.15–0.49 (reference group no contact)).
We found no association between aggressive EOL care and
cancer patients’ age, gender, marital status or financial status
(Table 2). No changes to the effect outcomes were found at
sensitivity analysis.
Discussion
We used pooled data from two mortality follow-back surveys
to examine the aggressiveness of EOL care received by 681
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Table 1 Socio-demographics, clinical characteristics and community health care service use of study sample
Entire
cohort
Patients not
experiencing
any aggressive
care
Patients
experiencing
aggressive care
QUALYCARE
cohort
QUALYCARE
patients
experiencing
aggressive care
IARE
cohort
IARE patients
experiencing
aggressive care
N % N % N % N % N % N % N %
681 100 277 40.7 404 59.3 554 100 299 54.0 127 100 105 82.7
Age in years
<60 67 9.8 33 11.9 34 8.4 67 12.1 34 11.4 0 0.0 0 0.0
60–69 141 20.7 49 17.7 92 22.8 112 20.2 66 22.1 29 22.8 26 24.8
70–79 191 28.1 69 24.9 122 30.2 140 25.3 82 27.4 51 40.1 40 38.1
80–89 228 33.5 105 37.9 123 30.5 190 34.3 91 30.4 38 29.9 32 30.5
90+ 54 7.9 21 7.6 33 8.2 45 8.1 26 8.7 9 7.1 7 6.7
Gender
Male 341 50.1 127 45.9 214 53.0 282 50.9 166 44.5 59 46.5 48 45.7
Female 340 49.0 150 54.2 190 47.0 272 49.1 133 55.5 68 53.5 57 54.3
Financial status
Living comfortably 323 48.1 142 51.6 181 45.6 273 49.9 138 46.9 50 40.0 43 41.8
Not living comfortably 349 51.9 133 48.4 216 54.4 274 50.1 156 53.1 75 60.0 60 58.3
Marital status
Married or with partner 323 50.6 147 54.7 176 47.7 289 53.2 147 50.5 34 35.8 29 37.2
Widowed 191 29.9 77 28.6 114 30.9 154 28.4 84 28.9 37 39.0 30 38.5
Divorced/Separated 59 9.3 20 7.4 39 10.6 47 8.7 29 10.0 12 12.6 10 12.8
Single 65 10.2 25 9.3 40 10.8 53 9.8 31 10.7 12 12.6 9 11.5
Living circumstances
Living alone 203 30.3 77 28.3 126 31.7 379 69.8 198 67.6 87 69.1 73 70.2
Living with others 466 69.7 195 71.7 271 68.3 164 30.2 95 32.4 39 31.0 31 29.8
Cancer type
Lung 145 21.3 63 22.7 82 20.3 119 21.5 64 21.4 26 20.5 18 17.1
Breast 52 7.6 28 10.1 24 5.9 47 8.5 20 6.7 5 3.9 4 3.8
Prostate 46 6.8 8 2.9 38 9.4 37 6.7 30 10.0 9 7.1 8 7.6
Gastrointestinal tract 167 24.5 78 28.2 89 22.0 157 28.3 81 27.1 10 7.9 8 7.6
Haematological 54 7.9 9 3.3 45 11.1 34 6.1 28 9.4 20 15.8 17 16.2
Cancer of unknown primary 61 9.0 20 7.2 41 10.2 47 8.5 28 9.4 43 33.9 13 12.4
Othera 156 22.9 71 25.6 85 21.0 113 20.4 48 16.1 43 33.9 37 35.2
Mobility at 3 months before death
No problem 159 24.6 58 21.8 101 26.6 132 25.0 78 27.5 27 23.1 23 24.0
Some problem 423 65.5 176 66.2 247 65.0 350 66.2 184 64.8 73 62.4 63 65.6
Confined to bed 64 9.9 32 12.0 32 8.4 47 8.9 22 7.8 17 14.5 10 10.4
Self-care at 3 months before death
No problem 262 41.1 93 35.5 169 45.0 212 40.6 128 45.7 50 43.1 41 42.7
Some problem 259 40.6 120 45.8 139 37.0 215 41.2 102 36.4 44 37.9 37 38.5
Unable to self-care 117 18.3 49 18.7 68 18.1 95 18.2 50 17.9 22 19.0 18 18.8
Activity at 3 months before death
No problem 137 21.3 40 15.2 97 25.6 106 20.2 71 25.2 31 26.5 26 26.8
Some problem 286 44.5 127 48.1 159 42.0 241 45.8 121 42.9 45 38.5 38 39.2
Unable to walk 220 34.2 97 36.7 123 32.5 179 34.0 90 31.9 41 35.0 33 34.0
Pain/Discomfort at 3 months before death
No pain 113 17.7 46 17.4 67 17.9 97 18.6 54 19.3 16 13.8 13 13.7
Some pain 392 61.4 158 59.9 234 62.4 322 61.6 179 63.9 70 60.3 55 57.9
Extreme pain 134 21.0 60 22.7 74 19.7 104 19.9 47 16.8 30 25.9 27 28.4
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deceased cancer patients. We found statistically and clinically
significant variations based on patients’ underlying cancer
type and their contact with community health care services.
Supporting previously published studies, we found that
patients with haematological cancers were more likely to ex-
perience aggressive EOL care compared to those with lung
cancer [16, 34]. Features related to both the disease process
and the discipline of haemato-oncology are likely to contrib-
ute to this effect, for example, chemotherapy remains the main
and often only form of therapy available, clinical trial involve-
ment is particularly high and haemato-oncology clinical ser-
vices have historically remained distinct from those of solid
tumours with less collaboration between disciplines, including
with palliative care [35]. Our finding that patients with pros-
tate cancer also have an increased risk of experiencing aggres-
sive EOL care is interesting, and additional research exploring
patterns of acute care towards the EOL by cancer sub-groups
is warranted. In our sample, although the proportion of pros-
tate cancer patients who spent ≥30 days in hospital during the
last 3 months of life was similar to patients with other cancer
types, we found that prostate cancer patients were more likely
to have greater than or equal to two ED visits in the last
3 months of life and/or die in hospital (Table 4 Appendix). Met-
astatic bone disease is commonly seen in patients with advanced
prostate cancer, and complications from this pattern of disease
spread, in particular pathological fractures, typically result in
ED visits. This may explain some of the higher rates of ED use
that we found in our sub-group of prostate cancer patients;
however, further research exploring this finding is required.
Our finding of lower odds of aggressive EOL care associated
with GP home visits supports Almaawiy and colleagues [25].
In their study of 9467 cancer decedents in Canada, increased
family physician visits were associated with reduced odds for
both hospital death and an ED visit in the last 2 weeks of life
[25]. However, Almaawiy et al. found that patients with great-
er than four visits per week had increased odds of
hospitalisations and hospital death, the opposite of our study
which found that care was less aggressive for patients who had
greater than five GP home visits than for those who had one to
five or no GP visits.
Our data support growing observational and experimental
evidence that community palliative care is associated with
lower odds of aggressive EOL care [9, 24, 36, 37]. Expansion
of palliative care services may therefore be one approach to-
wards helping address the current capacity crises faced by
many acute health care systems. Of note, the effect size found
in our study (AOR 0.27, 95 % CI 0.15–0.49) was greater than
those previously reported which may be related to our study
time period (the last 3 months of life) as this is longer than
those reported by several similar studies [20, 37]. This is par-
ticularly relevant given the small but emerging body of evi-
dence indicating a greater reduction in risk of patients
Table 1 (continued)
Entire
cohort
Patients not
experiencing
any aggressive
care
Patients
experiencing
aggressive care
QUALYCARE
cohort
QUALYCARE
patients
experiencing
aggressive care
IARE
cohort
IARE patients
experiencing
aggressive care
N % N % N % N % N % N % N %
681 100 277 40.7 404 59.3 554 100 299 54.0 127 100 105 82.7
Anxiety/Depression at 3 months before death
No anxiety/depression 223 35.5 91 35.1 132 35.8 176 34.1 97 35.0 47 42.0 35 38.0
Some anxiety/depression 316 50.3 128 49.4 188 51.0 267 51.7 146 52.7 49 43.8 42 45.7
Extreme anxiety/depression 89 14.2 40 15.4 49 13.3 73 14.2 34 12.3 16 14.3 15 16.3
Number of GP home visits during the last 3 months of life
None 181 31.4 46 19.1 135 40.3 138 29.2 96 37.9 43 41.8 39 47.6
1–5 338 58.7 159 66.0 179 53.4 287 60.7 141 55.7 51 49.5 38 46.3
>5 57 9.9 36 14.9 21 6.3 48 10.2 16 6.3 9 8.7 5 6.1
Community palliative care
No 205 31.2 36 13.2 169 43.9 156 29.0 121 42.2 49 40.8 48 49.0
Yes 453 68.8 237 86.8 216 56.1 382 71.0 166 57.8 71 59.2 50 51.0
District nurse
No 227 34.7 56 20.8 171 44.4 172 32.2 121 42.2 55 45.8 50 51.0
Yes 427 65.3 213 79.2 214 55.6 362 67.8 166 57.8 65 54.2 48 49.0
a Other cancers included those of the urinary tract (5.0 %), gynaecological (3.8 %), central nervous system (3.8 %) and skin (1.8 %) with percentage
figures referring to entire cohort data
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receiving aggressive EOL care with earlier palliative care in-
volvement [9, 37, 38]. Further investigation of the effect ac-
cording to timing of palliative care interventions is necessary.
Several previously published studies have reported that
men and patients of lower financial status have an increased
risk of experiencing aggressive EOL care [15, 16, 20–22, 25,
26, 34]. In our study, although we found a similar pattern, our
results for these factors did not reach statistical significance.
This may be related to our study sample size which when
compared to similar studies reporting significant findings is
much smaller, with the later mostly analysing population-
based routinely collected data. We also used a subjective mea-
sure of financial hardship which in health research in less
common than objective socio-economic status measures
70.3
82.9
62.1
29.7
17.1
37.9
40.7
39.9
15.9
3.5
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Indicators of aggressive EOL care and composite measure of all three indicators
No Yes 0 1 2 3
a b
c
Fig. 1 a Graph showing number of patients experiencing greater than or
equal to two emergency department (ED) visits in the last 3 months of
life, ≥30 days spent in hospital in the last 3 months of life and death in
hospital, and composite measure of aggressive end of life (EOL) care
calculated from these indicators for entire study cohort. b Graph showing
number of patients experiencing greater than or equal to two ED visits in
the last 3 months of life, ≥30 days spent in hospital in the last 3 months of
life and death in hospital, and composite measure of aggressive EOL care
calculated from these indicators for the QUALYCARE cohort of sample.
cGraph showing number of patients experiencing greater than or equal to
two ED visits in the last 3 months of life, ≥30 days spent in hospital in the
last 3 months of life and death in hospital, and composite measure of
aggressive EOL care calculated from these indicators for the IARE cohort
of sample
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[39]. Subjective assessments of financial status are valid alter-
natives to objective measures and are particularly valuable
when objective measures, which require responses to multiple
questions and are prone to having high levels of missing data,
Table 2 Findings from multivariable analysis for factors associated with cancer patients experiencing aggressive care during the last 3 months of life
Variable OR 95 % CI AOR 95 % CI
Age in years
<60 1.00 – – –
60–69 1.82 1.00–3.32 1.82 0.82–4.03
70–79 1.72 0.97–3.03 1.70 0.78–3.71
80–89 1.14 0.66–1.96 0.98 0.45–2.13
>90 1.53 0.73–3.18 1.44 0.49–4.26
Gender
Female 1.00 – – –
Male 1.33 0.98–1.81 1.35 0.84–2.18
Financial status
Living comfortably 1.00 – – –
Not living comfortably 1.27 0.94–1.74 1.34 0.88–2.05
Marital status
Married or with partner 1.00 – – –
Widowed 1.24 0.86–1.78 1.50 0.85–2.65
Divorced/Separated 1.63 0.91–2.92 1.04 0.48–2.24
Single 1.34 0.77–2.31 1.65 0.70–3.88
Cancer type
Lung 1.00 – – –
Breast 0.66 0.35–1.25 0.98 0.38–2.52
Prostate 3.65 1.55–8.58 4.36 1.39–13.70
Gastrointestinal tract 0.88 0.56–1.37 1.35 0.74–2.44
Haematological 3.84 1.70–8.68 4.16 1.38–12.47
Cancer of unknown primary 1.58 0.84–2.96 1.34 0.62–2.92
Other 0.92 0.58–1.45 0.91 0.48–1.74
Self-care at 3 months before death
No problem 1.00 – – –
Some problem 0.64 0.45–0.91 0.93 0.53–1.62
Unable to self-care 0.76 0.49–1.19 1.43 0.63–3.22
Activity at 3 months before death
No problem 1.00 – – –
Some problem 0.52 0.33–0.80 0.74 0.40–1.39
Unable to walk 0.52 0.33–0.83 0.69 0.31–1.49
Number of GP home visits during the last 3 months of life
None 1.00 – – –
1–5 0.38 0.26–0.58 0.59 0.35–1.00
>5 0.20 0.10–0.39 0.37 0.17–0.82
Community palliative care
No 1.00 – – –
Yes 0.19 0.13–0.30 0.27 0.15–0.49
District nurse
No 1.00 – – –
Yes 0.33 0.23–0.48 0.48 0.28–0.83
Numbers in bold represent statistically significant findings, p<0.05
OR odds ratio, 95 % CI 95 % confidence interval, AOR adjusted odds ratio
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are felt to be inappropriate [40, 41]. The lack of association
found between patient age and aggressive EOL care is incon-
sistent with the wider scientific literature where a decrease in
aggressiveness with increasing patient age has generally been
reported [15, 17, 20, 42, 43]. This requires further investiga-
tion but may reflect a specific change in UK policy towards
cancer treatment for older people, with equality legislation in
2012 [44].
We also found no association between aggressive EOL care
and cancer patients’ health status (mobility, ability to self-care,
activity level, pain/discomfort and anxiety/depression)
3 months prior to death, suggesting that socio-demographic
and/or environmental factors may be of greater importance
when determining the type of care that patients are likely to
receive towards the EOL. In a systematic review of place of
death by Gomes and Higginson in 2006, environmental fac-
tors were also found to bemore influential than factors relating
to the underlying illness [45]. These findings have important
policy implications when considering how future acute health
care services are delivered, especially given the ageing popu-
lation and anticipated rise in cancer cases [46].
Limitations
Mortality follow-back surveys have recognised limitations
primarily relating to the validity of bereaved caregivers’ re-
sponses as proxies for the decedents. For objective measures,
caregiver responses have been shown to have moderate to
good agreement with patients’; however, for subjective expe-
riences, such as pain or anxiety, less overall agreement has
been reported and it is therefore possible that the responses
received in our study may not be truly representative of the
patients’ experiences at that time [47, 48].
As is the case with all secondary analysis, our choice of
variables was limited by the data collected for the purposes of
the primary studies. For our dependent variable, this meant
that two of the three EOL care indicators that we used to
calculate our composite outcome measure have not them-
selves been validated (greater than or equal to two ED visits
in the last 3 months of life and ≥30 days in hospital in the last
3 months). However, both indicators were considered to be
clinically relevant and were based on well-established validat-
ed markers [5, 33]. The third indicator, death in hospital, is
commonly used as a marker of potentially aggressive EOL
care arising from consistent evidence that the majority of can-
cer patients would prefer to die at home [49]. With regard to
the independent variables investigated, we explored socio-
demographic factors, clinical characteristics and patient re-
ceipt of GP home visits, district nursing and community pal-
liative care. Further information regarding the local availabil-
ity of health and social care services was not available. As our
study included patients from across London, it is therefore
possible that regional variations in care provision, for
example, bed availability and/or community hospice services,
may have influenced the parameters that we used to define our
primary outcome of aggressive EOL care. Finally, because of
the different sampling approaches used by each of the primary
studies, the prevalence of aggressive EOL care in our pooled
sample may not be representative of, and therefore
generalisable to, the wider cancer population. However, these
different sampling approaches were not expected to impact the
factors associated with aggressive EOL care which was the
primary focus of our study, and benefits to pooling the datasets
included being able to explore the EOL care experiences of
patients receiving a range of different health care packages
including various levels of palliative care input. Furthermore,
the QUALYCARE study sampled participants according to
place of death, with deaths in hospital undersampled. It is
therefore likely that our estimation of aggressive EOL care,
which included death in hospital as one of its indicators, is
actually lower than that of the true population.
Conclusions
Our results reveal an association between aggressive care in
the last 3 months of life and a diagnosis of prostate or haema-
tological cancer. We also found that community health care
services, in particular contact with community palliative care,
are associated with a significant reduction in the odds of can-
cer patients receiving aggressive care towards the EOL. Ex-
pansion of such services may help address the current capacity
crises faced by many acute health care systems. Contrary to
earlier studies, we found that older age did not appear to in-
fluence the risk of cancer patients receiving aggressive EOL
care.
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Table 3 Eligibility criteria for each of the primary studies included in secondary analysis
Eligibility criteria Additional comments
QUALYCARE [27] Inclusion criteria The four Primary Care Trusts were specifically
chosen as they provided contrasting cancer
home death rates and contrasting deprivation
levels within London. The study sample was
then stratified by Primary Care Trust and place
of death so that in each area the sample
included all deaths that occurred at home, all
hospice deaths, all nursing home deaths, and a
random sample of NHS acute hospital deaths.
Study participants:
Bereaved relatives of people aged
≥18 years who died from cancer
over a 1-year period and who
lived in one of four London
Primary Care Trusts: Bromley,
Islington, Sutton and Merton or
Westminster
1.Deceased last resident in one of the four
following Primary Care Trusts as recorded in
the death registration: Bromley, Islington,
Sutton and Merton or Westminster.
2.Date of death registration within
4 to 10 months before sampling.
3.Deceased aged ≥18 at time of death.
4.Cancer (ICD10 codes C00–D48) recorded
as ‘underlying cause of death’ or in the
lowest completed cause of death line
in death certificate.
Exclusion criteria
1.Place of death other than an NHS acute
hospital, the deceased’s own home,
hospice or nursing home.
2.Place of death unknown.
3.Deaths registered by a coroner.
IARE [28]
Study participants:
Bereaved carers of older patients
who had accessed specialist
palliative care prior to death.
Inclusion criteria
1.Deceased aged ≥65 years at time of death
and had accessed specialist palliative care
prior to death.
2.Main informal carer aged ≥18 years and
known to the palliative care team as
the primary informal carer that was
most involved in providing information
and unpaid care for the patient.
3.Date of death registration within
4 to 10 months before sampling.
Exclusion criteria
1.Adults who did not provide informal
(unpaid) care of an eligible patient.
2.Carers aged <18 years.
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